In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
After receiving complaints from the SEC last spring, Biogen changed the way it reports upfront payments to collaborators in its quarterly updates. But it appears Biogen wasn’t the only one who got the message.
Several pharma giants — including Eli Lilly, Merck, Bristol Myers Squibb, AbbVie and Pfizer — are making similar changes in this year’s Q1 results, according to Market Watch, which first reported the news. The changes revolve around certain figures that don’t comply with Generally Accepted Accounting Principles, also known as non-GAAP measures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.